IMMUTEP Ltd
IMMP Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.10
KIRA · Stoqly’s AI analyst, in plain words
- IMMUTEP Ltd had $16.4M of revenue in fiscal 2026, up 144.9% on the year before. Over five years, revenue changed +40.8% a year on average.
- IMMUTEP Ltd lost $53.7M in fiscal 2026.
- Free cash flow was −$37.7M in fiscal 2026, −229.9% of revenue.
Market cap
$22.8M
P/E
—
Revenue
$16.4M
Net income
−$53.7M
Free cash flow
−$37.7M
Operating margin
—
IMMUTEP Ltd in 30 seconds · fiscal 2026
Are sales growing?
+144.9%
Yes. Sales grew 144.9% last year.
Does it make a profit?
−328.1%
No. It lost money last year.
Does profit turn into cash?
−229.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What IMMUTEP Ltd does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 20-F · Oct 23, 2026
- Legal name
- IMMUTEP Ltd
- CIK
- 0001506184
IMMUTEP Ltd · IMMP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.9M | $3.5M | $5.1M | $6.7M | $16.4M |
| Revenue growth | 65.6% | −28.7% | 46.9% | 30.1% | 144.9% |
| Net income | −$23.4M | −$26.8M | −$28.0M | −$39.8M | −$53.7M |
| Net margin | −476.6% | −767.2% | −544.9% | −594.6% | −328.1% |
| Diluted EPS | −$5.50 | −$6.02 | −$4.66 | −$5.46 | −$7.30 |
| Cash | |||||
| Cash from operations | −$21.9M | −$23.8M | −$22.8M | −$40.2M | −$37.6M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | $0.0M | $0.1M |
| Free cash flow | −$21.9M | −$23.8M | −$22.8M | −$40.2M | −$37.7M |
| FCF margin | −447.7% | −681.5% | −444.6% | −601.0% | −229.9% |
| Share count change | 42.7% | 5.1% | 34.6% | 21.2% | 1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $55.0M | $81.8M | $108M | $44.0M | $43.9M |
| Shareholders' equity | $64.7M | $90.4M | $126M | $93.8M | $42.4M |
| Current ratio | 14.2x | 13.8x | 18.2x | 11.7x | 5.7x |
| Returns and quality | |||||
| Return on equity | −39.1% | −34.6% | −25.9% | −36.2% | −78.9% |
| Return on tangible equity | −36.1% | −29.7% | −22.2% | −42.4% | −126.8% |
| Piotroski F-score | 4 | 2 | 4 | 1 | 2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
IMMUTEP Ltd · IMMP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.10 a share, the company is worth $22.8M.
Source: SEC EDGAR XBRL filings (CIK 0001506184). Data updated October 24, 2026. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.